The Esophageal Squamous Cell Carcinoma (ESCC) drugs in development market research report provides comprehensive information on the therapeutics under development for Esophageal Squamous Cell Carcinoma (ESCC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Esophageal Squamous Cell Carcinoma (ESCC). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Esophageal Squamous Cell Carcinoma (ESCC) and features dormant and discontinued products.
GlobalData tracks 152 drugs in development for Esophageal Squamous Cell Carcinoma (ESCC) by 106 companies/universities/institutes. The top development phase for Esophageal Squamous Cell Carcinoma (ESCC) is phase ii with 75 drugs in that stage. The Esophageal Squamous Cell Carcinoma (ESCC) pipeline has 148 drugs in development by companies and four by universities/ institutes. Some of the companies in the Esophageal Squamous Cell Carcinoma (ESCC) pipeline products market are: Jiangsu Hengrui Medicine, BeiGene and Chugai Pharmaceutical.
The key targets in the Esophageal Squamous Cell Carcinoma (ESCC) pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274), and Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC 2.7.10.1).
The key mechanisms of action in the Esophageal Squamous Cell Carcinoma (ESCC) pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with 25 drugs in Pre-Registration. The Esophageal Squamous Cell Carcinoma (ESCC) pipeline products include 12 routes of administration with the top ROA being Intravenous and 13 key molecule types in the Esophageal Squamous Cell Carcinoma (ESCC) pipeline products market including Monoclonal Antibody, and Small Molecule.
Esophageal Squamous Cell Carcinoma (ESCC) overview
Esophageal squamous cell carcinoma (ESCC) is a type of cancer that arises from the squamous cells lining the esophagus, the muscular tube connecting the throat to the stomach. Commonly associated with tobacco and alcohol use, as well as dietary factors, ESCC is prevalent in certain geographic regions. Symptoms often manifest late and include difficulty swallowing, weight loss, and chest pain. Diagnosis involves endoscopic procedures, biopsies, and imaging studies. Treatment modalities range from surgery and chemotherapy to radiation therapy, depending on the cancer’s stage and extent. Prognosis is generally guarded, underscoring the importance of early detection and comprehensive management strategies.
For a complete picture of Esophageal Squamous Cell Carcinoma (ESCC)’s pipeline drug market, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
